According to the present invention, S100A4 protein also known as Mts-1 interferes with the function of Annexin 2 and Annexin2/P11 tetramer by binding to Annexin 2. The present inventors have demonstrated that binding of S100A4 with Annaxin 2 modulates angiogenesis by interfering with Annexin 2 mediated tissue plasminogen activator (tPA) dependant conversion of plaminogen into plasmin and further conversion of plasmin into angiostatins. The present invention has further identified that the S100A4 protein binds to the N-terminal region of Annexin 2. Accordingly, the present invention discloses peptides and pharmaceutical compositions thereof and methods of treating cancers and other diseases that involve angiogenesis, by interfering with the interaction between S100A4 and Annexin

 
Web www.patentalert.com

< Truncated ADAMTS molecules

< Human and mouse beta-defensins, antimicrobial peptides

> CD7 as biomarker and therapeutic target for psoriasis

> Pentose derivatives as anti-hyperglycemic drugs

~ 00227